How Researchers Are Making Alzheimer’s Trials More Inclusive

Alzheimer’s doesn’t affect everyone equally. Hispanic and Black Americans are about 1.5 to 2 times more likely than white Americans to develop the disease. But when it comes to clinical trials, these groups are still underrepresented. That’s a problem. Without diversity in research, we can’t be sure how well new diagnostics and treatments work across […]

What’s the Difference Between Leqembi and Kisunla?

For almost two decades, people with Alzheimer’s disease had no new treatment options. In the 2020s, drugs called monoclonal antibodies received FDA approval for people in the earliest stages of Alzheimer’s disease. The two drugs approved in the U.S. so far — Leqembi and Kisunla — are both infusion-based drugs designed to target beta-amyloid plaques […]